Board of Directors

Neal Bhadkamkar, Ph.D.
Monitor Ventures

Neal Bhadkamkar is co-founder and Managing Partner of Monitor Ventures, the early stage venture capital affiliate of The Monitor Group. He focuses on systems, industrial and life-science companies that leverage advanced information technology. Prior to co-founding Monitor Ventures, Neal worked in senior engineering management at a startup, in business and research roles at a Silicon Valley based incubator, and in management consulting. Neal received an MBA from Harvard Business School, a PhD in Electrical Engineering from Stanford University, and a B. Tech. in Electrical Engineering from the Indian Institute of Technology, Delhi.

 

Datuk Franki Anthony Dass
Sime Darby Berhad

Datuk Franki Anthony Dass who started his career in Kumpulan Guthrie Berhad in 1980 as an Assistant Manager, has over 30 years of experience in the plantation industry. After various postings across Malaysia, Datuk Franki assumed the post of General Manager of PT Minamas in Indonesia in 2002. He subsequently became the Chief Operating Officer of PT Minamas in 2004, before assuming the post of Chief Executive Officer in 2007. He was appointed as the Executive Vice President of the Plantation Division in December 2010. Datuk Franki holds a Bachelor of Science degree in Agriculture from Universiti Pertanian Malaysia (now Universiti Putra Malaysia) and has attended various management and MBA programs with the Malaysian Institute of Management (MIM) and the Asian Institute of Management (AIM).

 

Luda Kopeikina
DSM Venturing

Ms. Kopeikina joined DSM, a global material-science-based company, in 2016 as Senior Investment Manager in its global corporate venturing arm. Before DSM, she was a Visiting Professor at the National University of Singapore where she co-founded the Institute for Engineering Leadership that nurtured 28+ start-up teams based on breakthrough technology. Luda is an entrepreneur who started three successful companies. One of them was BioEnergy Planet Inc., which converted agricultural waste into bio-oil. Before starting her own companies, Luda was a CEO of a public company, Celerity Solutions Inc, which she turned around and grew six-fold in two years and VP of General Electric where she restructured business processes to deliver multi-million dollar bottom line impact. Luda is an author of a popular book The Right Decision Every Time: How to Reach Clarity on Tough Decisions, published by Prentice Hall. She is currently a board member of Verdezyne, WattGlass, QD Solar and VioCare. Luda holds a Master’s Degree from MIT’s Sloan School of Management as a Sloan Fellow and a Master’s Degree in Computer Science from St. Petersburg University, Russia, where she also completed a Ph.D. thesis in Computer Science.

 

E. William Radany, Ph.D.
President and CEO

E. William Radany has over 30 years experience in the biotechnology industry. Prior to joining Verdezyne, he was the President and CEO of High Throughput Genomics, Inc., a provider of novel array-based gene expression assay technology for the life science industry. Previously, Dr. Radany was President of Biacore and founder and CEO of NeoGenex. Dr. Radany has held executive positions at Xencor, Caliper Technologies and Stratagene, where he helped establish business relationships with major pharmaceutical and biotechnology companies. Dr. Radany has spoken at numerous conferences and has invented several patents over the past 30 years. Dr. Radany received his Bachelor of Science degree in Cell Biology from Colorado State University and a Ph.D. in Biochemistry/Physiology from the University of Wyoming.

 

Renaka Ramachandran
Sime Darby Berhad

Renaka joined Sime Darby in April 2011 as the Chief Financial Officer of the Plantation Division. Prior to assuming the post, she was an Executive Director of PricewaterhouseCoopers Malaysia. Renaka has over 18 years of experience in providing audit and business advisory services to clients, both local and public listed companies as well as multinationals, in various industries. Her current role now includes the financial oversight of companies within the Plantation Division. She is a Fellow of the Chartered Association of Certified Accountants and a member of the Malaysian Accounting Standards Board Working Group on ED 50 Biological Assets (IAS 41).

 

Azli Razali
Sime Darby Berhad

Azli Razali is currently the Head of Sime Darby Renewables, a special unit within the Plantation Division of Sime Darby.  He is focused on leveraging palm-based feed stocks from Sime Darby’s plantation business and converting them into value-added products. Previously, Azli was the Vice President of Group Strategy and Business Development for Sime Darby, as well as Senior Vice President, Education and Human Capital for Northern Corridor Implementation Authority. Prior to joining Sime Darby, Azli worked in the investment banking sector with Credit Suisse, specializing in mergers, acquisition and hostile takeover defense.  Azli holds a Bachelor of Arts and a master’s degree from Cambridge University. He is also a member of the Institute of Chartered Accountant of England and Wales (ICAEW).

 

Drew Senyei, M.D.

Dr. Senyei is a managing director at Enterprise Partners where he leads the life science practice. Drew focuses on investments in pharmaceuticals, biopharmaceuticals, diagnostics, medical devices and consumer healthcare. Drew has served on over 25 public and private boards including Adeza Biomedical, NuVasive, Corixa Corp., Ligand Pharmaceuticals, Nanogen, Inc., and Discovery Partners. He currently sits on the boards of Enterprise portfolio companies including: Anaborex, Ascenta Therapeutics, Celladon, Ceula, Complete Genomics, Genoptix, Ophthonix, and TargeGen.

 

Meghan Sharp, Ph.D.
BP Ventures

Ms. Sharp is a member of BP’s corporate venture team. Investments span the BP Group, focused on emerging, strategic technologies in five areas: bioenergy and biomaterials; energy efficiency and storage; carbon management; renewable power; and oil and gas. Ms. Sharp focuses on biobased investments for the team and serves on the board of Chromatin Inc., Biosynthetic Technologies, Verdezyne, and Taxon Biosciences. Ms. Sharp received her Ph.D. in microbial genetics from the University of California, San Francisco, performed post-doctoral work in plant genetics at the University of Chicago and the Carnegie Institution of Washington at Stanford University, and received her MBA from Columbia University.

 

Chad Waite
OVP Venture Partners

Mr. Waite has more than 25 years of experience in both the management and investment sides of emerging growth companies. In 1987, he left his post as General Partner at Hambrecht & Quist Venture Partners to join OVP Venture Partners. Prior to that, he was in marketing and sales management at Cobe Laboratories, Inc. in its cardiovascular medical products division. Mr. Waite earned an AB in History from Kenyon College and an MBA from Harvard University.